Health ยท Rwanda

Rwanda Launches Africa's First Trial of Long-Acting Malaria Prevention Injection

Rwanda has launched what is described as Africa's first clinical trial of a long-acting injectable drug to prevent malaria. The trial comes as drug resistance and climate change threaten progress against the disease. The available information does not give the drug's name, trial design, participants or timeline.

Rwanda has launched a clinical trial of a long-acting injectable drug for malaria prevention, which is described as the first such trial in Africa.

The trial is presented as a potential shift in how malaria is prevented. Malaria is a mosquito-borne illness, and the source says progress against it is being threatened by drug resistance and by climate change.

Long-acting injectable prevention is a different approach from measures that depend on repeated dosing, although the available information does not explain how the drug under study works or how long its protection is expected to last.

The available information does not name the drug or its developer. It also does not say who is funding or running the trial, where in Rwanda it is taking place, how many people are taking part, which phase it is in, or when results may be expected. Nor does it give the exact date of the launch.

Because of this, the account is limited to the launch of the trial and the reasons given for its significance. Any conclusions about the drug's safety, effectiveness or eventual availability would depend on trial results that have not been presented.

More reporting from Voice of Africans